Loading

Short Communication Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/immunology.1.022

Targeting the PI3K/AKT/mTOR/NFkB Axis in Ovarian Cancer

  • 1Department of Cancer Biology, Wake Forest University School of Medicine, and Comprehensive Cancer Center, Winston Salem, NC 27157, USA
  • 2Department of Pathology, Wake Forest University School of Medicine, and Comprehensive Cancer Center, Winston Salem, NC 27157, USA
  • 3Department of Urology, Wake Forest University School of Medicine, and Comprehensive Cancer Center, Winston Salem, NC 27157, USA
  • 4Wake Forest Baptist Health Sciences, Winston Salem, NC 27157, USA
+ Affiliations - Affiliations

Corresponding Author

Neveen Said, nsaid@wakehealth.edu

Received Date: January 26, 2020

Accepted Date: March 04, 2020

Abstract

Ovarian cancer stands as the most lethal gynecologic malignancy and remains the fifth most common gynecologic cancer. Poor prognosis and low five-year survival rate are attributed to nonspecific symptoms at early phases along with a lack of effective treatment at advanced stages. It is thus paramount, that ovarian carcinoma be viewed through several lenses in order to gain a thorough comprehension of its molecular pathogenesis, epidemiology, histological subtypes, hereditary factors, diagnostic approaches, and methods of treatment. Above all, it is crucial to dissect the role that the unique peritoneal tumor microenvironment plays in ovarian cancer progression and metastasis. This short communication seeks to underscore several important aspects of the PI3K/AKT/mTOR/NFκB pathway in the context of ovarian cancer and discuss recent advances in targeting this pathway.

Keywords

PI3K/AKT/mTOR/NFκB, Ovarian cancer, Therapeutic implication

Author Information X